In its report, Shaping the Future of Pharmaceutical R&D: Executing to a Vision of High Performance, Accenture noted that the leading-edge R&D groups are abandoning existing organizational barriers in favor of a networked, virtual, and flexible approach to R&D. Many thought leaders believe this approach can be best achieved through a shift from a closed, internal IT infrastructure to cloud computing services. Cloud computing provides organizations with the ability to quickly access variable computing power, software, and storage options that are closely aligned with its own business performance and needs, and to turn fixed capital hardware investment into manageable, transparent operational cost.
A growing number of pharma companies are using cloud computing services as a fast, inexpensive way to manage traditionally cumbersome, time-consuming…
Potential Benefits of Integrating EHR Data within Drug Development
Percentage of e-Pharma Physicians in U.S
JAMES AVALLONE. Senior Digital Healthcare Analyst, Manhattan Research, a pharmaceutical and healthcare market research company. For more information, visit manhattanresearch.com.
RICH COHEN. Principal, Deloitte Consulting LLC, the consulting arm of Deloitte, which provides audit, consulting, financial advisory, risk management, and tax services. For more information, visit deloitte.com. For more information, visit deloitte.com.
MIKE DERKACZ. VP, Marketing, CNS, Cephalon, a global biopharmaceutical company. For more information, visit cephalon.com.
MONIQUE LEVY. Senior Director of Research, Manhattan Research, a pharmaceutical and healthcare market
research company. For more information, visit manhattanresearch.com.
JOHN PELKOWSKI. Senior Director, Client Engagement, AstraZeneca, a pharmaceutical company focused on six therapy areas, including cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammatory. For more information, visit astrazeneca-us.com.